VTX-PID
Depletion of Neutralizing Antibodies against AAV
Key Facts
About Vivet Therapeutics
Vivet Therapeutics is a private, clinical-stage gene therapy company based in Paris, developing a pipeline of liver-directed AAV-based treatments for rare metabolic diseases such as Wilson's Disease, Cerebrotendinous Xanthomatosis (CTX), and Progressive Familial Intrahepatic Cholestasis (PFIC). A key differentiator is its VTX-PID platform, an imlifidase-based technology designed to deplete neutralizing antibodies against AAV, potentially enabling treatment for a broader patient population and allowing for re-dosing. The company has advanced its lead program, VTX-801 for Wilson's Disease, into clinical trials and has secured Orphan Drug designations from major regulatory agencies, supported by a seasoned leadership team and committed international investors.
View full company profile